The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Staff & Volunteers
    • The Antibody Society’s Standing Committees
    • Advisors
    • Sponsors
    • James S. Huston Antibody Science Talent Award
  • Society meetings
    • Antibody Engineering & Therapeutics (US) 2020
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • Meeting reports
      • Keynote presentations
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2020
      • Antibody Engineering & Therapeutics Europe 2019
    • AIRR Community Meetings
    • FOCIS Symposia
    • Society-Funded Meetings
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Data Representation Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Minimal Standards Working Group
      • Software Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Antibodies in early-stage studies
    • Antibodies in late-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News You Should Know
    • Antibody therapeutics approved or in regulatory review in the EU or US
    • Research Resources
    • Education Resources
  • Career Center
  • Learning Center
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / About / Board of Directors / Jamie K. Scott

Jamie K. Scott

Jamie-ScottProfessor Jamie K. Scott holds joint appointments between the Department of Molecular Biology and Biochemistry and the Faculty of Health Sciences at Simon Fraser University in Burnaby, BC, Canada.

Professor Scott received her Ph.D. from the University of Missouri-Columbia in 1985 (Cell & Molecular Biology) and her M.D. from St. Louis University in 1989.  Her postdoctoral training was at the University of Missouri-Columbia in the lab of George P. Smith, the inventor of phage display, and at The Scripps Research Institute in the laboratories of John Tainer and Elizabeth Getzoff.  In 1993, she was recruited to Simon Fraser University as an Assistant Professor.

Dr. Scott was awarded a Tier 1 Canada Research Chair in Molecular Immunity in 2004.  She was a member of the Canadian Bacterial Diseases Network of Excellence and the Biotechnology Review Committee of the Science Council of B.C., and has served on a number of review committees for NIAID, NCI and IAVI. Her research has been supported by the NIH, Canadian Institutes of Health Research (CIHR) and the Natural Sciences & Engineering Research Council of Canada (NSERC).

Dr. Scott’s research career has centered on the study of antibody function, structure and genetics, and more recently, the cellular and genetic bases of the antibody response.  Her graduate thesis work focused on counting germline immunoglobulin Vl genes, her postdoc began with the initial development of phage-display library technology.  Having done her PhD on the antibody genetics, she used phage-displayed peptide libraries to understand antibody-antigen interactions, and to pursue design of peptide vaccines that would act as immunogenic mimics of discontinuous protein epitopes on pathogens.  Thus, she turned to HIV vaccines, by developing high affinity peptide ligands for 4 broadly neutralizing MAbs against HIV, and testing them as vaccines.  She also developed the filamentous phage itself as an immunogenic platform for conjugate vaccines, and has analyzed the B-cell responses to vaccination with phage in mice, and to HIV infection and SLE in humans.  Her laboratory has developed methods for sorting B-cell subsets from mice and humans, and analyzing their expressed antibody-gene repertoires by high throughput DNA sequencing, to provide insights into the antibody response to HIV infection, autoimmune disease (SLE) and vaccination.  Her lab is also cloning and expressing antibody genes of interest from these immune responses.  This ongoing work has been done in collaboration evolutionary geneticist, Felix Breden, who has aided with bioinformatic analyses of expressed antibody VH gene sequences. More recently Drs. Scott and Breden have been working to bring together the community studying antibody/B-cell receptor and T-cell receptor gene repertoires, so as to develop standards for the field, for publication, and for developing a common repository for sharing such data.

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Successful AIRR Community Meeting V January 15, 2021
  • Antibody Discovery in the Cloud: Using NGS to expand the universe of selectable antibodies January 13, 2021
  • AIRR Community and PrecisionFDA COVID-19 Precision Immunology App-a-thon December 28, 2020

Archives

Follow us online

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals